Investigations of the Serum Free Light Chain Ratio According to the Updated 2014 IMWG Diagnostic Criteria for Multiple Myelomain Korean Patients with Newly Diagnosed Multiple Myeloma.
Yang HS et al. Clin Lab. 2017 Oct 1;63(10):1765-1769. doi: 10.7754/Clin.Lab.2017.170341.
Monitoring multiple myeloma by idiotype-specific peptide binders of tumor-derived exosomes.
Iaccino E et al. Mol Cancer. 2017 Oct 13;16(1):159. doi: 10.1186/s12943-017-0730-8.
Chromothripsis in Treatment Resistance in Multiple Myeloma.
Lee KJ et al. Genomics Inform. 2017 Sep;15(3):87-97. doi: 10.5808/GI.2017.15.3.87. Epub 2017 Sep 28.
Automatic digital quantification of bone marrow myeloma volume in appendicular skeletons – clinical implications and prognostic significance.
Nishida Y et al. Sci Rep. 2017 Oct 10;7(1):12885. doi: 10.1038/s41598-017-13255-w.
DKK1 and sclerostin are early markers of relapse in multiple myeloma.
Marilee C et al. Bone. 2017 Oct 6. pii: S8756-3282(17)30370-8. doi: 10.1016/j.bone.2017.10.004. [Epub ahead of print].
Sodium fluoride PET imaging as a quantitative pharmacodynamic biomarker for bone homeostasis during anti-DKK1 therapy for multiple myeloma.
Wang Y et al. Blood Cancer J. 2017 Oct 6;7(10):e615. doi: 10.1038/bcj.2017.95.
Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation.
Takamatsu H et al. Ann Oncol. 2017 Oct 1;28(10):2503-2510. doi: 10.1093/annonc/mdx340.
Current applications of multiparameter flow cytometry in plasma cell disorders.
Jelinek T et al. Blood Cancer J. 2017 Oct 20;7(10):e617. doi: 10.1038/bcj.2017.90.